WEBULL
News
CYCN
1.260
+3.28%
0.040
Weekly Report: what happened at CYCN last week (0202-0206)?
Weekly Report · 3d ago
Watching Cyclerion Therapeutics; Zacks Small-Cap Research Gives Stock $8.00 Price Valuation
Benzinga · 02/02 17:07
Weekly Report: what happened at CYCN last week (0126-0130)?
Weekly Report · 02/02 09:02
Weekly Report: what happened at CYCN last week (0119-0123)?
Weekly Report · 01/26 09:02
Weekly Report: what happened at CYCN last week (0112-0116)?
Weekly Report · 01/19 09:02
Weekly Report: what happened at CYCN last week (0105-0109)?
Weekly Report · 01/12 09:02
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 01/08 09:25
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 01/07 17:05
Dow Jumps Over 400 Points; US Services Activity Falls In December
Benzinga · 01/06 17:58
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 01/06 17:05
US Stocks Mixed; Nasdaq Gains Over 50 Points
Benzinga · 01/06 14:49
Cyclerion, Medsteer form strategic anesthetic technology alliance
TipRanks · 01/06 14:02
Market-Moving News for January 6th
Benzinga · 01/06 12:11
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 01/06 12:05
Cyclerion Expands Partnership With Medsteer; Plans Phase 2 Trial Of CYC-126 In 2H 2026; Stock Up
NASDAQ · 01/06 11:41
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/06 09:45
Cyclerion Therapeutics Stock Jumps on Partnership With Medsteer for Depression Treatment
Dow Jones · 01/05 22:38
Cyclerion Therapeutics Partners With Medsteer for Depression Treatment
Dow Jones · 01/05 21:29
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/05 21:05
Cyclerion Therapeutics enters exclusive collaboration with Medsteer
TipRanks · 01/05 21:05
More
Webull provides a variety of real-time CYCN stock news. You can receive the latest news about Cyclerion Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CYCN
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.